Infliximab licensing expands to include halting arthritis progression.
C A
CA
Thompson
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy* / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab